| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000045 | Autophagosome assembly | Increases phenotype | PMID:32981224 |
| GO:0001843 | Neural tube closure | Decreases phenotype | PMID:28263823 |
| GO:0002072 | Optic cup morphogenesis involved in camera-type eye development | Decreases phenotype | PMID:28263823 |
| GO:0006171 | Camp biosynthetic process | Affects phenotype | PMID:11886533 |
| GO:0006695 | Cholesterol biosynthetic process | Decreases phenotype | PMID:34890705 |
| GO:0006749 | Glutathione metabolic process | Affects phenotype | PMID:34890705 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:32981224 |
| GO:0007040 | Lysosome organization | Increases phenotype | PMID:32981224 |
| GO:0007190 | Activation of adenylate cyclase activity | Decreases phenotype | PMID:11886533 |
| GO:0008284 | Positive regulation of cell population proliferation | Decreases phenotype | PMID:18694951 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:31330226 |
| GO:0034199 | Activation of protein kinase a activity | Decreases phenotype | PMID:11886533 |
| GO:0042311 | Vasodilation | Increases phenotype | PMID:15772515 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:32981224 |
| GO:0044754 | Autolysosome | Increases phenotype | PMID:32981224 |
| GO:0046466 | Membrane lipid catabolic process | Decreases phenotype | PMID:1884432 |
| GO:0051350 | Negative regulation of lyase activity | Increases phenotype | PMID:31330226 |
| GO:0051354 | Negative regulation of oxidoreductase activity | Increases phenotype | PMID:31330226 |
| GO:0055007 | Cardiac muscle cell differentiation | Decreases phenotype | PMID:29337257 |
| GO:0060037 | Pharyngeal system development | Decreases phenotype | PMID:28263823 |
| GO:0090030 | Regulation of steroid hormone biosynthetic process | Affects phenotype | PMID:31330226 |
| GO:1901098 | Positive regulation of autophagosome maturation | Increases phenotype | PMID:32981224 |
| GO:1902260 | Negative regulation of delayed rectifier potassium channel activity | Increases phenotype | PMID:22975497 |
| GO:1903609 | Negative regulation of inward rectifier potassium channel activity | Increases phenotype | PMID:22975497 |
| GO:1904878 | Negative regulation of calcium ion transmembrane transport via high voltage-gated calcium channel | Increases phenotype | PMID:22975497 |
| GO:2001259 | Positive regulation of cation channel activity | Increases phenotype | PMID:28603015 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.